Edition:
United States

Laboratory Corporation of America Holdings (LH.N)

LH.N on New York Stock Exchange

177.79USD
16 Feb 2018
Change (% chg)

$3.83 (+2.20%)
Prev Close
$173.96
Open
$173.68
Day's High
$179.00
Day's Low
$173.24
Volume
233,161
Avg. Vol
167,932
52-wk High
$181.65
52-wk Low
$134.49

Latest Key Developments (Source: Significant Developments)

LabCorp Reports Q4 Earnings Per Share $6.81
Tuesday, 6 Feb 2018 06:57am EST 

Feb 6 (Reuters) - Laboratory Corporation Of America Holdings ::LABCORP ANNOUNCES RECORD 2017 FOURTH QUARTER AND FULL YEAR RESULTS AND PROVIDES 2018 GUIDANCE.Q4 EARNINGS PER SHARE $6.81.Q4 REVENUE ROSE 13.2 PERCENT TO $2.7 BILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.30 TO $11.70.Q4 ADJUSTED EARNINGS PER SHARE $2.45.LABCORP SEES 2018 FREE CASH FLOW OF $1.1 BILLION TO $1.2 BILLION.Q4 EARNINGS PER SHARE VIEW $2.38, REVENUE VIEW $2.69 BILLION -- THOMSON REUTERS I/B/E/S.BACKLOG FOR COVANCE DRUG DEVELOPMENT AT END OF QUARTER WAS $7.13 BILLION.LABCORP SEES 2018 REVENUE GROWTH OF 9.5% TO 11.5% OVER 2017 RESTATED REVENUE OF $10.42 BILLION.‍DURING QUARTER, RECORDED A NET BENEFIT OF $519.0 MILLION IN NET EARNINGS, OR $5.00 PER SHARE, DUE TO IMPLEMENTATION OF TAX LAW​.EXPECTS ABOUT $2.8 BILLION OF BACKLOG IN COVANCE DRUG DEVELOPMENT TO CONVERT INTO REVENUE IN NEXT TWELVE MONTHS.FY2018 EARNINGS PER SHARE VIEW $10.79, REVENUE VIEW $11.03 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo
Wednesday, 15 Nov 2017 08:45am EST 

Nov 15 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo®.Laboratory Corporation Of America Holdings - ‍announced U.S. availability of PD-L1 ihc 28-8 pharmdx assay as complementary diagnostic for 2 indications in connection with use of Opdivo​.  Full Article

Labcorp - Co,‍ Capital Health announced that they have entered into a laboratory partnership​
Wednesday, 1 Nov 2017 08:45am EDT 

Nov 1 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp - Co,‍ Capital Health announced that they have entered into a laboratory partnership​.  Full Article

LabCorp reports Q3 adjusted earnings per share of $2.46
Wednesday, 25 Oct 2017 06:55am EDT 

Oct 25 (Reuters) - Laboratory Corporation Of America Holdings :LabCorp announces record third quarter results and increases 2017 guidance.Q3 adjusted earnings per share $2.46.Q3 earnings per share $1.74.Q3 revenue $2.6 billion versus I/B/E/S view $2.55 billion.Q3 earnings per share view $2.39 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $9.40 to $9.60.LabCorp - ‍backlog for covance drug development at end of quarter was $6.84 billion, which includes backlog from Chiltern acquisition of $1.0 billion ​.LabCorp - ‍expects approximately $2.7 billion of backlog in covance drug development to convert into revenue in next twelve months​.LabCorp - ‍sees 2017 free cash flow increased to $970 million to $1,010 million, up 8% to 13% over 2016​.LabCorp sees ‍for 2017 net revenue growth of 8.0% to 8.5% over 2016 net revenue of $9.44 billion​.FY2017 earnings per share view $9.50, revenue view $10.10 billion -- Thomson Reuters I/B/E/S.LabCorp says "‍revenue growth" in quarter "was negatively impacted by approximately 0.7% due to multiple hurricanes during quarter​".  Full Article

Luminex Corp - Labcorp agrees to extend commitment to Luminex Cystic Fibrosis
Monday, 11 Sep 2017 05:13pm EDT 

Sept 12 (Reuters) - Laboratory Corporation Of America Holdings :Luminex Corp - Agreement with Labcorp whereby Labcorp agreed to extend commitment to the Luminex Cystic Fibrosis product line through December 31, 2019.  Full Article

Chromadex sells its analytical testing business to LabCorp
Wednesday, 23 Aug 2017 08:30am EDT 

Aug 23 (Reuters) - Chromadex Corp :Chromadex sells its analytical testing business to LabCorp, to accelerate the expansion of Nicotinamide Riboside and its other patented ingredient technologies.Chromadex Corp - ‍upon closing of transaction, analytical testing services will be offered through LabCorp's Covance Food Solutions business​.  Full Article

Labcorp to acquire Chiltern for $1.2 bln in cash
Monday, 31 Jul 2017 06:00am EDT 

July 31 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp to acquire Chiltern for approximately $1.2 billion in cash, advancing its leadership in drug development.Labcorp - transaction expected to be accretive to Labcorp's adjusted earnings per share and free cash flow in year one.Labcorp - ‍once transaction is complete, Chiltern will become part of Labcorp's covance segment​.Labcorp - deal expected to be accretive to Labcorp's adjusted earnings per share and free cash flow in year one and earn cost of capital by year three​.Labcorp - Acquisition is an all-cash transaction, which labcorp expects to fund with a combination of bank financing and bonds.Labcorp says acquisition is an all-cash transaction.Labcorp says Labcorp expects to fund with a combination of bank financing and bonds.  Full Article

Labcorp Q2 adjusted earnings per share $2.47
Wednesday, 26 Jul 2017 06:57am EDT 

July 26 (Reuters) - Laboratory Corporation Of America Holdings :Labcorp announces record results in the second quarter of 2017 and increases 2017 guidance.Q2 adjusted earnings per share $2.47.Q2 earnings per share $1.82.Q2 revenue $2.5 billion versus I/B/E/S view $2.47 billion.Q2 earnings per share view $2.40 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $9.30 to $9.65.Labcorp sees 2017 free cash flow of $925 million to $975 million.Sees 2017 net revenue growth of 5.0% to 6.5% over 2016 net revenue of $9.44 billion.FY2017 earnings per share view $9.43, revenue view $9.86 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $9.43 -- Thomson Reuters I/B/E/S.Labcorp - ‍backlog at end of quarter was $5.53 billion, company expects approximately $2.1 billion of this backlog to convert into revenue in next twelve months​.Labcorp - company remains on track to deliver cost synergies of $100 million related to acquisition of Covance through three-year period ending in 2017.  Full Article

LabCorp, Novant Health extend laboratory services agreement
Tuesday, 11 Jul 2017 08:45am EDT 

July 11 (Reuters) - Laboratory Corporation Of America Holdings ::LabCorp and Novant Health extend laboratory services agreement.LabCorp - ‍under agreement, LabCorp diagnostics provides Novant Health with laboratory management services for all Novant Health Acute Care facilities​.  Full Article

QTS Realty Trust Q1 FFO per share $0.63
Monday, 1 May 2017 04:55pm EDT 

May 1 (Reuters) - Qts Realty Trust Inc :Q1 FFO per share $0.63.Q1 operating FFO per share $0.64.Sees 2017 operating ffo per share in range of $2.64 to $2.76 per share.Sees 2017 capital expenditures, excluding acquisitions, of approximately $325.0 million to $375.0 million.Labcorp says also maintaining its guidance for churn at high end of its historical average of 5-8% for 2017.Labcorp says continues to anticipate in 2017 adjusted ebitda margins to be in line with 2016 adjusted ebitda margins.Q1 FFO per share view $0.61 -- Thomson Reuters I/B/E/S.Fy2017 FFO per share view $2.70 -- Thomson Reuters I/B/E/S.  Full Article